Attention Deficit Hyperactivity Disorder Market by Therapies, Patient Type, Application - Global Forecast 2025-2030- Product Image

Sale

Attention Deficit Hyperactivity Disorder Market by Therapies, Patient Type, Application - Global Forecast 2025-2030

Report
182 Pages
October 2024
Region: Global
360iResearch™
ID: 6013867

UP TO €684EUR$697USD£571GBP OFF until Dec 31^st 2024

The Attention Deficit Hyperactivity Disorder Market grew from USD 14.99 billion in 2023 to USD 15.61 billion in 2024. It is expected to continue growing at a CAGR of 4.18%, reaching USD 19.98 billion by 2030.

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental condition characterized by symptoms such as inattention, hyperactivity, and impulsiveness, affecting children and adults globally. The necessity of addressing ADHD is underscored by its impact on educational performance, social interactions, and quality of life. Applications span from pharmaceutical treatments and behavioral therapies to education sector adaptations and digital health solutions. The end-use scope includes individual patients, educational institutions, healthcare providers, and pediatric specialists. The market is primarily driven by increasing ADHD diagnosis rates, heightened societal awareness, and advancements in genomic technologies for personalized treatments. There is a burgeoning opportunity in digital therapeutics and AI-driven diagnostic tools, which promise to optimize individualized treatment plans and facilitate remote monitoring. To capture these opportunities, companies should invest in partnerships with technological innovators and support regulatory pathways for digital therapy approvals. However, market growth is challenged by the stigma associated with ADHD, disparities in healthcare access, and varying diagnostic criteria across regions. Addressing these limitations requires cross-sector collaboration and advocacy for standardized treatment protocols. The landscape is ripe for innovation, particularly in non-pharmacological interventions, wearable health trackers, and the integration of big data analytics to refine diagnosis and treatment efficacy. Engaging in research that fosters evidence-based digital intervention can offer commercialization potential and broaden access to interventions. Additionally, exploring biosignal and neurofeedback technologies could revolutionize ADHD management strategies. Given the market's dynamic nature, companies should remain adaptable, emphasizing patient-centric approaches and continuous learning to stay ahead. Collaboration with academic institutions for clinical trials can facilitate novel discoveries and improve therapeutic offerings. Ultimately, firms should focus on holistic ADHD management approaches that encompass patient education, caregiver support, and technology integration, ensuring comprehensive solutions that adapt to evolving healthcare paradigms.

Understanding Market Dynamics in the Attention Deficit Hyperactivity Disorder Market

The Attention Deficit Hyperactivity Disorder Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.

Market Drivers
- Increasing prevalence of attention deficit hyperactivity disorder among children and adults worldwide
- Advancements in diagnostic tools and techniques for early detection of attention deficit hyperactivity disorder
- Growing awareness and educational initiatives about attention deficit hyperactivity disorder among parents and educators
- Surge in research and development activities for innovative treatment options in attention deficit hyperactivity disorder market
Market Restraints
- Lack of qualified mental health professionals with expertise in ADHD leading to delayed or incorrect diagnosis and treatment
Market Opportunities
- Innovative pharmaceutical formulations targeting symptom-specific relief for different age groups with ADHD
- Customized educational programs and tools designed to enhance learning experiences for children with ADHD
- Workplace accommodation solutions for adults with ADHD focusing on productivity and mental health improvement
Market Challenges
- High cost of ADHD diagnosis and treatment combined with limited insurance coverage reduces accessibility for patients

Exploring Porter’s Five Forces for the Attention Deficit Hyperactivity Disorder Market

Porter’s Five Forces framework further strengthens the insights of the Attention Deficit Hyperactivity Disorder Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Attention Deficit Hyperactivity Disorder Market

External macro-environmental factors deeply influence the performance of the Attention Deficit Hyperactivity Disorder Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Attention Deficit Hyperactivity Disorder Market

The Attention Deficit Hyperactivity Disorder Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Attention Deficit Hyperactivity Disorder Market

The Attention Deficit Hyperactivity Disorder Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Attention Deficit Hyperactivity Disorder Market

The Attention Deficit Hyperactivity Disorder Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Attention Deficit Hyperactivity Disorder Market, highlighting leading vendors and their innovative profiles. These include Akili Interactive Labs, Inc., Austedo Pharmaceuticals, Cingulate Therapeutics, LLC, Eli Lilly and Company, Ironshore Pharmaceuticals Inc., Janssen Pharmaceuticals, Inc., KemPharm, Inc., Medice Arzneimittel Pütter GmbH & Co. KG, Neos Therapeutics, Inc., NeuroSigma, Inc., NLS Pharmaceutics AG, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Shire Plc, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Attention Deficit Hyperactivity Disorder Market to forecast the revenues and analyze trends in each of the following sub-markets:

Therapies
- Pharmacotherapy
  - Non-Stimulants
  - Stimulants
- Psychotherapy
  - Behavioral Therapy
  - Cognitive Behavioral Therapy
  - Family Therapy
  - Social Skills Training
Patient Type
- In-Patients
- Out-Patients
Application
- Attention Deficit Disorder
- Hyperactive Disorder

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

What is the current size of the market, and how is it expected to grow?
Which products, segments, and regions present the most attractive investment opportunities?
What are the prevailing technology trends and regulatory factors influencing the market?
How do top vendors rank regarding market share and competitive positioning?
What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
4. Market Overview

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of attention deficit hyperactivity disorder among children and adults worldwide
5.1.1.2. Advancements in diagnostic tools and techniques for early detection of attention deficit hyperactivity disorder
5.1.1.3. Growing awareness and educational initiatives about attention deficit hyperactivity disorder among parents and educators
5.1.1.4. Surge in research and development activities for innovative treatment options in attention deficit hyperactivity disorder market
5.1.2. Restraints
5.1.2.1. Lack of qualified mental health professionals with expertise in ADHD leading to delayed or incorrect diagnosis and treatment
5.1.3. Opportunities
5.1.3.1. Innovative pharmaceutical formulations targeting symptom-specific relief for different age groups with ADHD
5.1.3.2. Customized educational programs and tools designed to enhance learning experiences for children with ADHD
5.1.3.3. Workplace accommodation solutions for adults with ADHD focusing on productivity and mental health improvement
5.1.4. Challenges
5.1.4.1. High cost of ADHD diagnosis and treatment combined with limited insurance coverage reduces accessibility for patients
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental

6. Attention Deficit Hyperactivity Disorder Market, by Therapies

6.1. Introduction
6.2. Pharmacotherapy
6.2.1. Non-Stimulants
6.2.2. Stimulants
6.3. Psychotherapy
6.3.1. Behavioral Therapy
6.3.2. Cognitive Behavioral Therapy
6.3.3. Family Therapy
6.3.4. Social Skills Training

7. Attention Deficit Hyperactivity Disorder Market, by Patient Type

7.1. Introduction
7.2. In-Patients
7.3. Out-Patients

8. Attention Deficit Hyperactivity Disorder Market, by Application

8.1. Introduction
8.2. Attention Deficit Disorder
8.3. Hyperactive Disorder

9. Americas Attention Deficit Hyperactivity Disorder Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Attention Deficit Hyperactivity Disorder Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Attention Deficit Hyperactivity Disorder Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation

List of Figures

FIGURE 1. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET RESEARCH PROCESS
FIGURE 2. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET, FPNV POSITIONING MATRIX, 2023

List of Tables

TABLE 1. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET DYNAMICS
TABLE 7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY NON-STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY SOCIAL SKILLS TRAINING, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY IN-PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY OUT-PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY ATTENTION DEFICIT DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY HYPERACTIVE DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 40. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 41. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 42. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 43. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 44. CANADA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 46. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 47. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 48. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 49. MEXICO ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 62. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 63. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 68. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 69. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 70. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 71. CHINA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 73. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 74. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 75. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 76. INDIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 78. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 83. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 84. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 85. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 86. JAPAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 88. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 89. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 93. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 98. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 103. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 108. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 113. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 114. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 115. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 116. THAILAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 118. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 119. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 128. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 129. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 130. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 131. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 132. DENMARK ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 134. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 135. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 136. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 137. EGYPT ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 139. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 140. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 141. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 142. FINLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 144. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 145. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 146. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. FRANCE ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 149. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 150. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 151. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 152. GERMANY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 154. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 158. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 159. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 160. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 161. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 162. ITALY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 169. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 174. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 175. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 176. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 177. NORWAY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 178. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 179. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 180. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 181. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. POLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 184. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 185. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 186. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 187. QATAR ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 204. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 205. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 206. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 207. SPAIN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 213. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 214. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 215. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 219. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 220. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 221. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 222. TURKEY ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PSYCHOTHERAPY, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET SHARE, BY KEY PLAYER, 2023
TABLE 234. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Attention Deficit Hyperactivity Disorder market, which are profiled in this report, include:

Akili Interactive Labs, Inc.
Austedo Pharmaceuticals
Cingulate Therapeutics, LLC
Eli Lilly and Company
Ironshore Pharmaceuticals Inc.
Janssen Pharmaceuticals, Inc.
KemPharm, Inc.
Medice Arzneimittel Pütter GmbH & Co. KG
Neos Therapeutics, Inc.
NeuroSigma, Inc.
NLS Pharmaceutics AG
Novartis AG
Otsuka Pharmaceutical Co., Ltd.
Pfizer Inc.
Shire Plc
Sunovion Pharmaceuticals Inc.
Supernus Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	182
Published	October 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 15.61 Billion
Forecasted Market Value ( USD ) by 2030	$ 19.98 Billion
Compound Annual Growth Rate	4.1%
Regions Covered	Global
No. of Companies Mentioned	18

License	Format	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access		This is a single user license, allowing one user access to the product.	€3481EUR$3,545USD£2,904GBP €3868EUR$3,939USD£3,227GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€6158EUR$6,272USD£5,138GBP €6843EUR$6,969USD£5,709GBP

Understanding Market Dynamics in the Attention Deficit Hyperactivity Disorder Market

Exploring Porter’s Five Forces for the Attention Deficit Hyperactivity Disorder Market

Applying PESTLE Analysis to the Attention Deficit Hyperactivity Disorder Market

Analyzing Market Share in the Attention Deficit Hyperactivity Disorder Market

Evaluating Vendor Success with the FPNV Positioning Matrix in the Attention Deficit Hyperactivity Disorder Market

Strategic Recommendations for Success in the Attention Deficit Hyperactivity Disorder Market

Key Company Profiles

Market Segmentation & Coverage

The report provides a detailed overview of the market, exploring several key areas:

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Global Market Report 2024

Attention Deficit Hyperactivity Disorder Market Size, Share & Trends Analysis Report by Drug Type (Stimulants, Non-stimulants), Demographics (Children, Adults), Distribution Channel, Region, and Segment Forecasts, 2024-2030

Attention-deficit/hyperactivity disorder (ADHD) - Market Insight, Epidemiology and Market Forecast - 2034

Attention Deficit Hyperactivity Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Attention Deficit Hyperactivity Disorder Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

About the Attention Deficit Hyperactivity Disorder Drug Market